Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -2.07%75 Revenue per Share is BDT16.07 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 75/100 and a GF Value™ of BDT19.48 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 381 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 91.34% on this metric.
Orion Pharma's revenue per share for the
three
months ended in Mar. 2026 was BDT6.35.
Orion Pharma's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT16.07.
Warning Sign:
Orion Pharma Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Orion Pharma was -39.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -25.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -7.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -3.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Orion Pharma's Revenue per Share or its related term are showing as below:
DHA:ORIONPHARM'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25 Med: -3.3 Max: 22.1
Current: -25
During the past 12 years, Orion Pharma's highest 3-Year average Revenue Per Share Growth Rate was 22.10% per year. The lowest was -25.00% per year. And the median was -3.30% per year.
DHA:ORIONPHARM's 3-Year Revenue Growth Rate is ranked worse than 91.34% of 381
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.2
vs DHA:ORIONPHARM: -25.00
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Orion Pharma Revenue per Share Related Terms
Orion Pharma Revenue per Share Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Revenue per Share Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma PS Ratio vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Orion Pharma's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Orion Pharma's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT16.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Revenue per Share of BDT16.07 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #348 out of 381 companies in the Utilities - Independent Power Producers industry, placing it in the top 91.3%.
Is Orion Pharma's Revenue per Share too high?
Orion Pharma's current Revenue per Share is BDT16.07. Based on the distribution chart, Orion Pharma ranks #348 out of 381 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Revenue per Share compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #348 out of 381 companies for Revenue per Share. This places Orion Pharma in the lower half of its industry. The industry median Revenue per Share is 0.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for an Utilities - Independent Power Producers company?
The median Revenue per Share among Utilities - Independent Power Producers companies is 0.20, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Revenue per Share is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Revenue per Share is BDT16.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.48, compared to a current price of BDT23.70 — trading 21.7% above its estimated fair value. The current Revenue per Share is BDT16.07. Orion Pharma's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Revenue per Share is BDT16.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT23.70 is trading 21.7% above its estimated GF Value™ of BDT19.48.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Revenue per Share: BDT16.07
GF Value™: BDT19.48 vs. price of BDT23.70 (21.7% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
75GF Score
Get the complete analysis for DHA:ORIONPHARM
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
